MYLAN N.V. (NASDAQ:MYL) Files An 8-K Costs Associated with Exit or Disposal ActivitiesItem 2.05.
MYLAN N.V. (NASDAQ:MYL) Files An 8-K Costs Associated with Exit or Disposal Activities
Costs Associated With Exit or Disposal Activities.
On December 5, 2016, Mylan N.V. (“Mylan” or the “Company”) announced restructuring programs in certain locations representing initial steps in a series of actions that are anticipated to further streamline its operations globally. Since 2015, the Company has made a number of significant acquisitions, and as part of the holistic, global integration of these acquisitions, the Company is focused on how to best optimize and maximize all of its assets across the organization and across all geographies. As part of this process, the Company anticipates that less than 10 percent of its global workforce may be impacted across all geographies and businesses.
The Company is currently developing the details of the cost reduction initiatives, including workforce actions and other potential restructuring activities beyond the programs already announced. Further details will be disclosed as initiatives are finalized, including the estimated amount or range of amounts to be incurred and future cash expenditures associated with those initiatives.
Forward-Looking Statements.
This report includes statements that constitute “forward-looking statements,” including that the Company anticipates that less than 10 percent of its global workforce may be impacted across all geographies and businesses. These statements are made to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any regulatory, legal, or other impediments to Mylan’s ability to execute on its integration plans and the other risks detailed in Mylan’s filings with the Securities and Exchange Commission. Mylan undertakes no obligation to update these statements for revisions or changes after the date of this release.
About MYLAN N.V. (NASDAQ:MYL)
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent. MYLAN N.V. (NASDAQ:MYL) Recent Trading Information
MYLAN N.V. (NASDAQ:MYL) closed its last trading session up +0.21 at 35.86 with shares trading hands.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent. MYLAN N.V. (NASDAQ:MYL) Recent Trading Information
MYLAN N.V. (NASDAQ:MYL) closed its last trading session up +0.21 at 35.86 with shares trading hands.